Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Clinical Genitourinary Cancer

Volumn 11, Issue 4, 2013, Pages 423-430

  Linton, Anthony ^a,b   Pond, Greg ^c   Clarke, Stephen ^d   Vardy, Janette ^a,b   Galsky, Matthew ^e   Sonpavde, Guru ^f  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e Mt Sinai Tisch Cancer Institute   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Inflammation; Malignancy; mGPS; Neutrophil lymphocyte ratio; Prognosis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; DOCETAXEL; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GLASGOW PROGNOSTIC SCORE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

INFLAMMATION; MALIGNANCY; MGPS; NEUTROPHIL-LYMPHOCYTE RATIO; PROGNOSIS;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; POSITION-SPECIFIC SCORING MATRICES; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL; TAXOIDS;

EID: 84888003207     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.020     Document Type: Article

References (40)

1. W.R. Berry, J. Laszlo, and E. Cox Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate Cancer 44 1979 763 775
2. L.J. Emrich, R.L. Priore, and G.P. Murphy Prognostic factors in patients with advanced stage prostate cancer Cancer Res 45 1985 5173 5179
3. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
4. A.J. Armstrong, E.S. Garrett-Mayer, and Y.C. Yang A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403
5. A.J. Armstrong, I.F. Tannock, and R. de Wit The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer 46 2010 517 525
6. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
7. â̂§)
8. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
9. L.K. Dennis, C.F. Lynch, and J.C. Torner Epidemiologic association between prostatitis and prostate cancer Urology 60 2002 78 83
10. A. Sciarra, F. Di Silverio, and S. Salciccia Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52 2007 964 972
11. A.M. De Marzo, E.A. Platz, and S. Sutcliffe Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269
12. D. Mauri, G. Pentheroudakis, and C. Tolis Inflammatory prostate cancer: an underestimated paraneoplastic clinical manifestation Urol Oncol 23 2005 318 322
13. P.S. Weinstein, M. Skinner, and J.D. Sipe Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases Scand J Immunol 19 1984 193 198
14. M. Ishizuka, H. Nagata, and K. Takagi C-reactive protein is associated with distant metastasis of T3 colorectal cancer Anticancer Res 32 2012 1409 1415
15. C.S.D. Roxburgh, and D.C. McMillan Role of systemic inflammatory response in predicting survival in patients with primary operable cancer Future Oncol 6 2009 149 163
16. A.B.C. Crumley, D.C. McMillan, and M. McKernan Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer Br J Cancer 94 2006 637 641
17. A.M.A. Murri, J.M.S. Bartlett, and P.A. Canney Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer Br J Cancer 94 2006 227 230
18. R. Zahorec Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill [Article in English, Slovak] Bratisl Lek Listy 102 2001 5 14
19. B. Azab, M. Zaher, and K.F. Weiserbs Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction Am J Cardiol 106 2010 470 476
20. B.K. Duffy, H.S. Gurm, and V. Rajagopal Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention Am J Cardiol 97 2006 993 996
21. X. An, P.R. Ding, and Y.H. Li Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer Biomarkers 15 2010 516 522
22. W. Chua, K.A. Charles, and V.E. Baracos Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer Br J Cancer 104 2011 1288 1295
23. S.C. Kao, N. Pavlakis, and R. Harvie High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 2010 5805 5813
24. H. Ubukata, G. Motohashi, and T. Tabuchi Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients J Surg Oncol 102 2010 742 747
25. G. Sonpavde, V. Matveev, and J.M. Burke Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer Ann Oncol 23 2012 1803 1808
26. D.C. McMillan, J.E. Crozier, and K. Canna Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer Int J Colorectal Dis 22 2007 881 886
27. G. Garcea, N. Ladwa, and C.P. Neal Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma World J Surg 35 2011 868 872
28. O. Smaletz, H.I. Scher, and E.J. Small Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 2002 3972 3982
29. K. Shafique, M.J. Proctor, and D.C. McMillan Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study Prostate Cancer Prostatic Dis 2012 195 201
30. G.R. Pond, A.J. Armstrong, and B.A. Wood Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy BJU Int 110 11 Pt B 2012 E461 E468
31. A. Dabaja, M. Menon, and P. Agarwal Prognostic indicators of aggressive disease in patients with locally advanced or metastatic prostate cancer: A focus on neutrophil to lymphocyte and platelet to lymphocyte ratios J Clin Oncol 29 suppl 2011 abstract 62
32. D. Keizman, M. Ish-Shalom, and N. Maimon Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model J Clin Oncol 30 suppl 2012 abstract 37
33. G. Sonpavde, G.R. Pond, and S.J. Clarke Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial J Clin Oncol 30 suppl 2012 abstract 4644
34. W. Chua, S.J. Clarke, and K.A. Charles Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer Support Care Cancer 20 2012 1869 1874
35. C. De Nunzio, G. Kramer, and M. Marberger The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation Eur Urol 60 2011 106 117
36. N. Rajarubendra, N. Lawrentschuk, and D.M. Bolton Prostate cancer immunology - an update for urologists BJU Int 107 2011 1046 1051
37. J.-L. Luo, W. Tan, and J.M. Ricono Nuclear cytokine-activated IKK[agr] controls prostate cancer metastasis by repressing Maspin Nature 446 2007 690 694
38. V. Gennaro, D. Ugolini, and P. Viarengo Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002) Eur J Cancer 41 2005 2709 2714
39. J. Nakashima, M. Tachibana, and Y. Horiguchi Serum interleukin 6 as a prognostic factor in patients with prostate cancer Clin Cancer Res 6 2000 2702 2706
40. S.H. Aaltoma, P.K. Lipponen, and V.M. Kosma Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer Anticancer Res 21 2001 3101 3106